Cigna Group Files 8-K for Other Events and Exhibits

TL;DR

**Cigna Group filed an 8-K on Feb 15, 2024, for 'Other Events' and 'Financial Statements and Exhibits', but the specific details are missing from this text.**

AI Summary

The Cigna Group filed an 8-K on February 15, 2024, reporting an event that occurred on February 14, 2024. The filing indicates 'Other Events' and 'Financial Statements and Exhibits' but the specific details, names, or dollar amounts related to these events are not provided in the excerpt.

Why It Matters

An 8-K filing signals a potentially significant corporate event, but without the specific details of the 'Other Events' or 'Financial Statements and Exhibits', the real-world impact on Cigna Group or its stakeholders cannot be determined from this excerpt.

Risk Assessment

Risk Level: medium — The provided text is only the header and initial metadata of the 8-K, lacking the actual content of the reported events, making a risk assessment impossible.

Key Players & Entities

• Cigna Group (company) — registrant
• February 14, 2024 (date) — date of earliest event reported
• February 15, 2024 (date) — filing date
• Delaware (location) — state of incorporation
• 900 Cottage Grove Road, Bloomfield, Connecticut 06002 (location) — principal executive offices

FAQ

Key Financial Figures

• $0.01 — ch registered Common Stock, Par Value $0.01 CI New York Stock Exchange , Inc. I
• $3.2 billion — e Company will purchase an aggregate of $3.2 billion of the Company's common stock as part o

Filing Documents

• cigna8k.htm (8-K) — 25KB
• ex99-1.htm (EX-99.1) — 9KB
• image_001.jpg (GRAPHIC) — 4KB
• 0000950159-24-000100.txt ( ) — 212KB
• ci-20240214.xsd (EX-101.SCH) — 3KB
• ci-20240214_lab.xml (EX-101.LAB) — 33KB
• ci-20240214_pre.xml (EX-101.PRE) — 22KB
• cigna8k_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On February 14, 2024, The Cigna Group ("Cigna" or the "Company") entered into accelerated share repurchase agreements (collectively, the "ASR Agreements") with Deutsche Bank AG and Bank of America, N.A. (collectively, the "Dealers"). Under the ASR Agreements, the Company will purchase an aggregate of $3.2 billion of the Company's common stock as part of its existing share repurchase program. Under the terms of the ASR Agreements, on February 15, 2024, Cigna will receive an aggregate initial delivery of approximately 7.6 million shares in exchange for a prepayment of $3.2 billion. The specific number of shares that the Company will ultimately repurchase under the ASR Agreements will be determined based on the volume-weighted average price of Cigna's common stock during the terms of the transactions, less a discount and subject to adjustments pursuant to the terms and conditions of the ASR Agreements. At final settlement, under certain circumstances the Dealers may be required to deliver additional shares of Cigna common stock to the Company, or in other circumstances, Cigna may be required to deliver, at its discretion, either shares of its common stock or cash to the Dealers. Final settlement of the ASR Agreements is expected to occur during the second quarter of 2024. The ASR Agreements contain customary terms for these types of transactions, including, but not limited to, the mechanisms to determine the number of shares or the amount of cash that will be delivered at final settlement, the required timing of delivery of the shares, the specific circumstances under which final settlement of the transactions may be accelerated or extended or the ASR Agreements may be terminated early by Cigna or the Dealers, and various acknowledgments, representations and warranties made by the Company and the Dealers to one another. The terms of the ASR Agreements are subject to adjustment under certain circumstances. Each of the Dealers perform normal

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release dated February 15, 2024. 104 Cover Page Interactive Data File (formatted in Inline XBRL). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. the Cigna group Date: February 15, 2024 By: /s/ Brian C. Evanko Brian C. Evanko Executive Vice President and Chief Financial Officer and President and Chief Executive Officer, Cigna Healthcare

View Full Filing

View this 8-K filing on SEC EDGAR